

# CURRICULUM VITAE ET STUDIORUM

## Doctor Giuseppe Galati

### ➤ PERSONAL INFORMATION



Date of birth: 25/03/1984  
Place of birth: Catanzaro (CZ), Italy  
Nationality/ citizenship: Italy  
Gender: Male  
e-mail: giuseppe.galati5@gmail.com; giuseppe.galati@multimedica.it  
ORCID 0000-0002-8001-1249  
GOOGLE SCHOLAR: [https://scholar.google.com/citations?hl=en&user=bPg\\_EcQAAAAJ](https://scholar.google.com/citations?hl=en&user=bPg_EcQAAAAJ)  
Twitter: [https://twitter.com/GiuseppeGalati\\_](https://twitter.com/GiuseppeGalati_)  
Linkedin: <https://www.linkedin.com/in/giuseppe-galati-5b14b257/>

### ➤ CLINICAL POSITION AND HOSPITAL APPOINTMENTS

- **SENIOR CONSULTANT CARDIOLOGIST – HEART FAILURE AND CARDIOMYOPATHIES SPECIALIST** at **DIVISION OF CARDIOLOGY, CARDIOVASCULAR DEPARTMENT, I.R.C.C.S. MULTIMEDICA, CARDIOVASCULAR SCIENTIFIC INSTITUTE, SESTO SAN GIOVANNI, MILAN, ITALY. MARCH 2023 – PRESENT.**
- **CONSULTANT CARDIOLOGIST - HEART FAILURE AND CARDIOMYOPATHIES SPECIALIST** at **HEART FAILURE UNIT, DIVISION OF CLINICAL CARDIOLOGY, CARDIOVASCULAR AND THORACIC DEPARTMENT, SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE (I.R.C.C.S.), MILAN, ITALY. RESPONSIBLE FOR THE HEART FAILURE AND CARDIOMYOPATHIES CENTER. MAY 2017 – DECEMBER 2022.**
- **CARDIOLOGIST** in the **CARDIOVASCULAR ER/HUB OF SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE (IRCCS), MILAN, ITALY. MARCH 2020 – NOVEMBER 2022, during the Covid19 pandemic.**
- **CONSULTANT CARDIOLOGIST and MAIN SCIENTIST** at **THE INTERNATIONAL CENTRE FOR EDUCATION AND RESEARCH IN CARDIOVASCULAR PATHOLOGY AND CARDIOVISUALIZATION – SAMARA MEDICAL STATE HOSPITAL, RUSSIA. JANUARY 2022 – PRESENT.**
- **CONSULTANT CARDIOLOGIST** at **DELFO MED CENTER SRL, Via F.lli Cervi Residenza Portici - Milano Due, Segrate (MILAN), ITALY. SEPTEMBER 2021 – PRESENT.**
- **CONSULTANT CARDIOLOGIST** at **AUGUSTO MEDICAL CENTER SRL, “SPAZIO MAUGERI”, Largo Augusto, MILAN, ITALY. DECEMBER 2019 – PRESENT.**
- **CONSULTANT CARDIOLOGIST – HEART FAILURE AND CARDIOMYOPATHIES SPECIALIST** at **CARDIOLOGY UNIT, CARDIOVASCULAR DEPARTMENT, I.R.C.C.S. POLICLINICO SAN DONATO, UNIVERSITY-HOSPITAL, SAN DONATO MILANESE, MILAN, ITALY. JUNE 2016 – JANUARY 2017**
- **STAFF CARDIOLOGIST - TENURED MEDICAL OFFICER** at **S. ANNA UNIVERSITY-HOSPITAL, FERRARA, ITALY. Co-RESPONSIBLE OF HEART FAILURE AND CARDIOMYOPATHIES CENTER. SEPTEMBER 2015 – MARCH 2016**
- **Substituted Physician of General Practitioners. Bologna, Italy. July 2009**

### ➤ ACADEMIC STUDIES

- **July 2002: Pre-University Studies: ITALIAN SECONDARY SCHOOL DIPLOMA:** Classical Certificate at “Liceo Classico P. Galluppi” of Catanzaro, Italy. Grade 100/100 cum laude.
- **11<sup>th</sup> June 2008: GRADUATION IN MEDICINE AND SURGERY – SCHOOL OF MEDICINE, UNIVERSITY OF BOLOGNA “Alma Mater Studiorum”** (age at graduation: 24), Italy. Final degree grade **110/110 cum laude**. Official time duration of the degree course: 6 years (2002-2008). Thesis title: “*Cardiac Amyloidosis: Clinical, Morphological and Pathophysiological analogies and differences between the three main aetiological types*”.
- **10<sup>th</sup> February 2009: POST-GRADUATE STUDIES – ITALIAN BOARD EXAMINATION: LICENSED TO WORK AS MEDICAL DOCTOR – SCHOOL OF MEDICINE, UNIVERSITY OF BOLOGNA “Alma Mater Studiorum”, Italy.**
- **20<sup>th</sup> May 2015: POST-GRADUATE SPECIALIZATION IN CARDIOVASCULAR DISEASES - INSTITUTE OF CARDIOVASCULAR DISEASES, UNIVERSITY OF BOLOGNA “Alma Mater Studiorum”/ Saint Orsola-Malpighi University-Hospital** (age at specialization 31), Italy. Final degree grade **110/110 cum laude**. Official time duration of specialization course: 5 years (2010-2015). Thesis title: “*Histologic and histometric characterization of myocardial fibrosis in End-Stage Hypertrophic Cardiomyopathy: clinical and pathological comparison in 31 explanted hearts*”.
- **14<sup>th</sup> December 2017: SECOND LEVEL MASTER IN CLINICAL COMPETENCE IN HEART FAILURE 2017 -** Organized by the **UNIVERSITY OF FLORENCE AND BY THE ITALIAN ASSOCIATION OF HOSPITAL CARDIOLOGISTS (ANMCO), Italy.** Final degree grade **110/110 cum laude**. Official time duration of specialization course: 1 year (2017). Project work title: “*Advanced Heart Failure in Hypertrophic Cardiomyopathy: from clinical-pathological phenotypes to clinical, instrumental and therapeutic management*”.

- **16<sup>th</sup> Jan 2019 – 31<sup>st</sup> Jan 2021: POSTGRADUATE COURSE IN HEART FAILURE LONDON.** Organized by THE ZURICH HEART HOUSE and endorsed by the **British Society for Heart Failure** and by the **British Cardiovascular Society**; based on the curriculum of the ESC Heart Failure Association (HFA). At the end of the course achievement of **CERTIFICATE IN HEART FAILURE MANAGEMENT**.

- **BRIEF DESCRIPTION OF THE PRE-GRADUATE AND POST-GRADUATE EDUCATION:**

**2007-2010.** Medical Student and Medical Doctor at Cardiovascular Department of S. Orsola-Malpighi University-Hospital of Bologna (mentor Prof. C. Rapezzi)

**2009-2010.** Medical Doctor at Cardiovascular Radiology Unit of S. Orsola-Malpighi University-Hospital of Bologna, (mentor Prof. R. Fattori) in particular Cardiovascular Magnetic Resonance (CMR) and Cardiovascular Computed Tomography (CT).

### ➤ **PROFESSIONAL ASSOCIATIONS, MEMBERSHIPS AND SCIENTIFIC BOARDS**

- **FELLOW OF THE HEART FAILURE ASSOCIATION OF THE ESC :** MARCH 2021- PRESENT
- **MEMBER OF THE STUDY GROUP ON CARDIOMYOPATHIES 2020-2022 OF HEART FAILURE ASSOCIATION (HFA) OF THE ESC**
- **MEMBER OF THE STUDY GROUP ON MYOCARDITIS 2018-2020 OF HEART FAILURE ASSOCIATION (HFA) OF THE ESC**
- **HEART FAILURE SPECIALISTS OF TOMORROW (HoT) REPRESENTATIVE AND COORDINATOR FOR ITALY :** OCTOBER 2021 - PRESENT
- **CONSULTANT FOR YOUNG COMMUNITY (AREA GIOVANI) OF ANMCO :** APRIL 2019 – DECEMBER 2021
- **MEMBER OF THE SCIENTIFIC COMMITTEE OF SICOA :** APRIL 2019 – DECEMBER 2021
- **MEMBER OF THE STUDY GROUP ON RIGHT AND LEFT HEART FAILURE OF THE ITALIAN SOCIETY OF CARDIOLOGY (SIC):** APRIL 2023 – PRESENT.
- **ITALIAN FEDERATION OF CARDIOLOGY (IFC) YOUNG AMBASSADOR FOR HEART FAILURE ASSOCIATION (HFA) OF THE ESC:** 2019- PRESENT.
- **ITALIAN HEART FAILURE ASSOCIATION (ITAHFA) MEMBER:** MAY 2022 – PRESENT.
- ✓ **EUROPEAN SOCIETY OF CARDIOLOGY – ESC (Professional Member):** January 2011-present
- ✓ **HEART FAILURE ASSOCIATION – HFA (Gold Member):** January 2011-present
- ✓ **EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING – EACVI (Silver Member):** January 2011-present
- ✓ **EACVI HEART IMAGERS OF TOMORROW – HIT:** January 2011-present
- ✓ **HEART FAILURE SPECIALIST OF TOMORROW – HoT:** April 2015-present
- ✓ **ESC Scientist of Tomorrow – SoT:** August 2015 - December 2018
- ✓ **ESC WORKING GROUP OF MYOCARDIAL AND PERICARDIAL DISEASES:** April 2016 – present
- ✓ **AMERICAN COLLEGE OF CARDIOLOGY – ACC:** April 2020 – present
- ✓ **AMERICAN HEART ASSOCIATION – AHA:** September 2016 -present
- ✓ **ITALIAN FEDERATION OF CARDIOLOGY – IFC:** August 2011-present
- ✓ **ITALIAN SOCIETY OF CARDIOLOGY – SIC:** August 2011-present:
- ✓ **ITALIAN ASSOCIATION OF HOSPITAL CARDIOLOGISTS – ANMCO:** February 2016-present
- ✓ **ITALIAN SOCIETY OF CARDIOLOGY OF PRIVATE HOSPITALS – SICOA:** October 2018-present

### ➤ **CARDIOLOGY AREA OF SUBSPECIALITY**

- **CERTIFICATION OF COMPETENCE IN HEART FAILURE, HEART FAILURE CERTIFICATION EXAM. HEART FAILURE ASSOCIATION (HFA) OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC):** Awarded on May 2016.
- **SECOND LEVEL MASTER IN CLINICAL COMPETENCE IN HEART FAILURE 2017 -** Organized by the **UNIVERSITY OF FLORENCE** and by the **ITALIAN ASSOCIATION OF HOSPITAL CARDIOLOGISTS (ANMCO), Italy.**
- **CERTIFICATE IN HEART FAILURE MANAGEMENT** after participating in **POSTGRADUATE COURSE IN HEART FAILURE LONDON.** Organized by the **ZURICH HEART HOUSE** and promoted by the **BRITISH SOCIETY FOR HEART FAILURE** and the **BRITISH CARDIOVASCULAR SOCIETY**, based on the curriculum of the **ESC Heart Failure Association (HFA)**
- **Advanced Heart Failure, LVAD and Heart Transplantation. Cardiomyopathies and rare genetic cardiovascular diseases responsible for Sudden Cardiac Death.**
- **EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING (EACVI) OF EUROPEAN SOCIETY OF CARDIOLOGY (ESC): LEVEL 1 CERTIFICATION IN CARDIOVASCULAR MAGNETIC RESONANCE (CMR).** Awarded on May 2017.
- **Advanced Cardiovascular Imaging (3D-Echocardiography, CMR), Cardiovascular Pathology.**

### ➤ **SCIENTIFIC RESEARCH ACTIVITY**

- 2013-2016: research collaboration with the cardiovascular division of Pathology Department (Dr. O. Leone) at S.Orsola-Malpighi University-Hospital of Bologna on cardiomyopathies and rare cardiovascular disease responsible for sudden cardiac death and advanced heart failure which leads to heart transplantation.

- 2013-2016: **Principal Investigator** of a **multicentre research project** on myocardial fibrosis and on pathophysiology of end-stage hypertrophic cardiomyopathy. Particular focus on genetics, histopathology and on the new techniques of tissue characterization with Cardiovascular Magnetic Resonance (T1 mapping, ECV etc..)
- 2010- 2016: research collaboration with Prof. C. Rapezzi on infiltrative myocardial diseases (cardiac amyloidosis and sarcoidosis).
- January 2019- **Coordinator** of Scientific Research within **European University-Hospital Alliance Project on Heart Failure**, Division of Clinical Cardiology, IRCCS Ospedale San Raffaele, Milano, Italia.

### ➤ **TEACHING AND ACADEMIC ACTIVITY**

- **ACADEMIC YEARS 2019/2020; 2020/2021: TEACHER OF CARDIOLOGY** on the topic **HEART FAILURE, SCHOOL OF SPECILIZATION IN CARDIOVASCULAR DISEASES** at the **VITA-SALUTE UNIVERSITY OF SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE**, Milan, Italy.
- **ACADEMIC YEARS 2019/2020; 2020/2021; 2021/2022: TEACHER OF CARDIOLOGY** (topic **HEART FAILURE** and **CARDIOMYOPATHIES**), **SCHOOL OF MEDICINE AND SURGERY** at the **UNIVERSITY VITA SALUTE OF SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE**, Milan, Italy.
- **ACADEMIC YEARS 2020/2021; 2021/2022: TEACHER OF CARDIOLOGY** (topic **HEART FAILURE**), **SCHOOL OF ODONTOIATRICS AND DENTAL PROSTHESIS** at the **UNIVERSITY VITA SALUTE OF SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE**, Milan, Italy.
- **20 January 2020. ACADEMIC LESSON FOR THE SCHOOL OF SPECIALIZATION IN CARDIOVASCULAR DISEASES** at the **UNIVERSITY OF BRESCIA** (Director Prof M. Metra: “Heart Failure: from RCTs, to Guidelines, to how building an HF center to future perspectives).
- **ACADEMIC YEARS 2021/2022; 2022/2023 TUTOR FOR THE QUALIFYING INTERNSHIP FOR THE MEDICAL STUDENTS** of the **SCHOOL OF MEDICINE AND SURGERY, VITA-SALUTE UNIVERSITY OF SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE**, Milan, Italy.

### ➤ **ACTIVITY AS EDITOR AND PEER REVIEWER**

- **EDITOR** for “**Minerva Cardiology and Angiology**”: November 2020 – Present.
- **EDITOR** for “**EC Cardiology UK**”: March 2019 – August 2021.
- **ASSOCIATE EDITOR** for **Frontiers in Cardiovascular Medicine - Heart Failure and Transplantation Section**: January 2022-May 2022
- **EDITOR** for **Cardiac Failure Review – Radcliffe Cardiology**: January 2022- present
- **Twitter Editor** for **European Journal of Heart Failure**: October 2019 – December 2020
- **Twitter Editor** for **ESC Heart Failure**: October 2019 – February 2020.
- **Reviewer** for the following Journals
  - **Heart** as certified by the Cleveland clinic – Center for continuing education: February 2014 – December 2016.
  - **ESC Heart Failure** as certified by Wiley Online Library and by Prof. Anker: December 2017 – Present
  - **Journal of the American College of Cardiology (JACC)**: January 2019 – Present
  - **Cardiology**: April 2019 – Present
  - **JACC Case Reports**: April 2019 – May 2020.
  - **Minerva Cardiology and Angiology**: May 2020 – Present.
  - **European Heart Journal – Acute Cardiovascular Care**: June 2020 – Present.
  - **Heart Failure Reviews (HREV)**: August 2020 – Present.
  - **Open Heart** : January 2022 – Present
  - **Therapeutics and Clinical Risk Management**: January 2022 – Present
  - **European Heart Journal**: May 2022 – Present
  - **Journal of Cardiac Failure**: December 2022 – Present
  - **Journal of the American College of Cardiology (JACC) Heart Failure**: January 2023 – Present
  - **International Journal of Cardiology**: March 2023 – Present
  - **European Journal of Heart Failure**: June 2023 – Present

### ➤ **EXPERIENCE IN MULTICENTRE INTERNATIONAL TRIALS**

Investigator of the following multicentre international trials carried out according to **good clinical practice criteria (GCP) certified by Novartis** on November 2017 & by **The Global Health Network** on November 2019

- **FOURIER Trial**: **Coinvestigator & Coordinator** of S.Orsola-Malpighi University-Hospital, Bologna, Italy. The aim of this trial is to demonstrate that the additional LDL-C lowering with Evolocumab (a monoclonal antibody against PCSK9) with respect to standard therapy (including statins) decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization in subjects with clinical evident ischemic post-infarction heart disease, peripheral artery disease, or with previous stroke.
- **COMMANDER-HF Trial**: **Coinvestigator** of S. Anna University-Hospital, Ferrara, Italy The aim of this trial is to demonstrate that the novel oral anticoagulant rivaroxaban added to standard therapy of ischemic heart disease and of heart failure can decrease the risk of total and cardiovascular death, and of major adverse cardiovascular events.

- **GALACTIC-HF Trial:** Coinvestigator & Coordinator of IRCCS Ospedale San Raffaele, Milan, Italy. The aim of this trial is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on cardiovascular death, first HF event (included HF hospitalization) and all-cause death in subjects with chronic HF with reduced ejection fraction (HFrEF) receiving standard of care (SoC) therapy.
- **PARALLAX Trial:** Coinvestigator & Coordinator of San Raffaele Hospital & Scientific Institute (IRCCS), Milan, Italy. The aim of this study is to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with HFpEF.
- **ARIADNE:** Coinvestigator & Coordinator of San Raffaele Hospital & Scientific Institute (IRCCS), Milan, Italy. European non interventional study with prospective collection of data for two groups of HFrEF patients: symptomatic patients who receive the current standard of care (SoC) for the treatment of HFrEF and patients who receive sacubitril/valsartan on top of SoC.
- **BLITZ-HF:** Coinvestigator & Coordinator of San Raffaele Hospital & Scientific Institute (IRCCS), Milan, Italy. Italian non interventional study with prospective collection of data for HF patients. The aim of this study is to improve adherence to the HF guidelines of the European Society of Cardiology (ESC) and result in the best patient care for patients with acute and chronic heart failure.
- **Observational serial chart review of Repatha® use in European subjects with Hyperlipidaemia (Study 20130296):** Coinvestigator & Coordinator of San Raffaele Hospital & Scientific Institute (IRCCS), Milan, Italy. European non interventional study with prospective collection of data for patient on treatment with evolocumab. The aim of this study is to review the clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.
- **FINEHEARTS-HF:** Coinvestigator & Coordinator of San Raffaele Hospital & Scientific Institute (IRCCS). The aim of this study is to evaluate safety and efficacy of Finerenone on morbidity and mortality in HF patients (NYHA II-IV) with an LVEF>40%.

#### ➤ **ADDITIONAL SKILLS**

- September 2011: **Basic Life Support ANMCO-AHA (BLS-D) Certification** (performance 93%): Institute of Cardiovascular Diseases - S.Orsola-Malpighi University-Hospital, Bologna, Italy.
- February 2021: **Re-Training BLS (special for Covid19) c/o San Raffaele Hospital & Scientific Institute (IRCCS)**, Milan, Italy.
- March 2014: **Advanced Cardiac Life Support ANMCO-AHA (ACLS) Certification** (performance 90%): Institute of Cardiovascular Diseases - S.Orsola-Malpighi University-Hospital, Bologna, Italy.

#### ➤ **INTERVENTIONAL PROCEDURES**

<b>As second operator: n° 378</b>	
Coronary Angiography: n° 195	Percutaneous Coronary Intervention: n° 98
Ventriculography: n° 7	Aortography: n° 30
IVUS (Intra Vascular Ultrasound): n° 10	Thromboaspiration: n° 6
Intra-Aortic Balloon Pump Insertion: n° 10	
Percutaneous Aortic Valvuloplasty: n° 13	Percutaneous Mitral Valvuloplasty: n° 1
Pericardiocentesis: n° 2	Temporary Pacemaker Implantation: n° 10
Permanent Pacemaker Implantation and/or Upgrade and Pacemaker Pocket Revision: n° 13	Permanent Pacemaker Replacement: n° 5
Implantable Cardioverter Defibrillator (ICD) Implantation: n° 8	ICD Replacement: n° 4
Transcatheter Ablation and Electro-anatomical Mapping: n° 4	Electro-physiological Study: n° 4
Right Heart Catheterization: n° 131	Endomyocardial Biopsy: n° 83
Pulmonary Artery Angiography: n° 4	Central Venous Catheter Implantation: n° 1

<b>As first operator: n° 4</b>	
Right Heart Catheterization: n° 4	Endomyocardial Biopsy: n° 3

The sum of each procedure may be higher than the total number, because in the same session more procedures could have been performed.

#### ➤ **NON-INVASIVE INSTRUMENTAL DIAGNOSIS**

Trans-Thoracic Echocardiography (TTE): n° 5000

Trans-Oesophageal Echocardiography (TOE): n° 45

External electrical cardioversion: n° 120

ECG, Holter-ECG, exercise ECG test (treadmill test): thousands of ECG (not exactly quantifiable number), hundreds of Holter-ECG (not exactly quantifiable number), more than 400 exercise ECG tests.

Cardiopulmonary Exercise Test (CPET): n° 75

#### ➤ **CONGRESSES AND COURSES**

##### **AS ATTENDANT (ONLY EUROPEAN AND INTERNATIONAL CONGRESSES ARE REPORTED):**

- **Erasmus Course Cardiovascular MRI with CT correlation** (13-14 October 2008, Bologna).
- **Euroecho 2009** (9-12 December 2009, Madrid).
- **8<sup>th</sup> European Course on congenital heart disease** (23-26 October 2013, Bologna)
- **Brainstorming on heart rate and beta-blockers: an international perspective** (10-11 September 2014, Bologna).



- **FOURIER Investigator Meeting** (24 February 2015, Rome)
- **European symposium on rare cardiovascular diseases** (4-6 March 2015, Naples)
- **III Florence international symposium on advances in cardiomyopathies - 12th meeting of the European Myocardial and Pericardial diseases working group of the European Society of Cardiology** (22-24 October 2015).
- **EuroEcho Imaging 2018** (5-8 December 2018, Milan). During this congress, he was named by the ESC: “ESC twitter ambassador for EuroEcho Imaging 2018”.
- **European Society of Cardiology Congress 2020** (29 Agosto – 1 Settembre 2022, Online).
- **European Society of Cardiology Congress 2022** (26 – 29 Agosto 2022, Barcelona & Online).

#### **AS SPEAKER, MODERATOR AND DISCUSSANT (ALL THE CONGRESSES ARE REPORTED):**

- **EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2015** (29 August – 2 September 2015, London). During this congress he gave **two poster presentation**: the 30<sup>th</sup> of August Top 80 poster in the Basic and Translational Research, category: Cardiomyopathy PR7, and the 2<sup>nd</sup> of September at Basic Science Poster area, Poster number 90542.
- **76<sup>TH</sup> NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF CARDIOLOGY** (11-14 December 2015, Rome). During this congress he gave a presentation of an **oral abstract**: “Histologic and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: clinical and pathological comparison in 31 explanted hearts”
- **HEART FAILURE 2016** (21-24 May 2016, Florence), during this congress he gave **a poster presentation** the 21<sup>st</sup> May 2016, and he was **one of the 15 cardiologists selected to participate in the HFA career café**.
- **EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016** (27 - 31 August 2016, Rome). During this congress he gave **a moderated poster presentation** (28<sup>th</sup> of August 2016): “Extent, type, patterns and distribution of myocardial fibrosis in end-stage HCM: an histologic-histometric analysis of 30 explanted hearts and comparison of LGE-CMR with histological fibrosis”, session: ‘Improving Diagnosis in Cardiomyopathies’.
- **EuroCMR 2017** (25 - 27 May, Prague), during this congress he gave a **presentation of an oral abstract** (25<sup>th</sup> of May 2017): “Comparison between LGE-CMR and histomorphometric quantification of myocardial fibrosis in transplanted hearts for end-stage hypertrophic cardiomyopathy (HCM)”, session: “Advanced Tissue Characterization”. Moreover, he was **one of the 20 cardiologists selected to participate in the Speed Mentoring Programme**.
- **HIGHLIGHTS SICOA: HEART FAILURE** (18 November 2017, Milan). During this congress he gave three presentations on Heart Failure.
- **78<sup>TH</sup> NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF CARDIOLOGY** (15-18 December 2017, Rome). During this congress he gave a **presentation**: “Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts”; section YOUNG SIC Area “**Highlights Young Researcher – Published papers**”.
- **HEART FAILURE 2030 - CUTTING EDGE CARE OF THE FAILING heart** (23-24 April 2018, Pisa). During this congress he participated, as **discussant**, to the **session “Multimodality Imaging in Heart Failure”**.
- **HEART FAILURE 2018** (26-29 May 2018, Vienna). During this congress he gave **a poster presentation**: the 28<sup>th</sup> of May category: Cardiomyopathy, Poster number P1906. Furthermore, he was named by the ESC: “ESC Twitter Ambassador for Heart Failure 2018”.
- **49<sup>TH</sup> NATIONAL CONGRESS OF THE ITALIAN ASSOCIATION OF HOSPITAL CARDIOLOGISTS (ANMCO 2018)**. During this congress he gave a **presentation of an oral abstract** (1<sup>st</sup> of June 2018): “Clinical-pathological profiles responsible for advanced heart failure, heart transplantation, left ventricular assist device implantation and death for heart failure in Hypertrophic cardiomyopathy”, session: “Heart Failure - Device”. This presentation was awarded as one of the best contribution of the entire congress.
- **FOCUS ON HEART FAILURE: NEW THERAPEUTIC TARGETS** (15th June 2018, Milan), **San Raffaele Hospital and Scientific Institute**. During this congress he gave **4 presentations on HF**.
- **EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018** (25-29 August 2018, Munich). During this congress he gave **two poster presentations** (26<sup>th</sup> of August 2018) in the session: “Hypertrophic Cardiomyopathy”: “Clinicopathological profiles responsible for advanced heart failure, heart transplantation, left ventricular assist device implantation and death for heart failure in Hypertrophic cardiomyopathy” e “Coronary microvascular pathology as the major determinant of severe fibrosis in end-stage hypertrophic cardiomyopathy (HCM)”. Furthermore, he was named by the ESC: “ESC twitter ambassador for ESC Congress 2018”.
- **HEART FAILURE: NOT END-STAGE BUT NEW STAGE 4TH EDITION** (13-14 September 2018, Rome). He participated as **moderator** during the session: “**Doctor to Doctor: Meet the HOT (Heart Failure of Tomorrow)**”.
- **Clinical Management of DOAC: Atrial Fibrillation: focus on management of special clinical contest**. He was discussant and presenter of: “Pharmacological interaction and complex patients”
- **SICOA REGIONAL CONGRESS (Lombardy): Updating in Cardiology** (24 November 2018, Milan). He gave a **presentation** during the session “Heart Failure”, with the following title: “**Left Heart Failure: from the guidelines to the medical therapy**”

- **COMPARED EXPERIENCES: A QUESTION OF LIHFE** (National Congress on Heart Failure, 8-9 March 2019, Rome): He was **presenter and discussant** during the **Workshop “Guideline: Instructions for Use”** (Teacher G. Di Tano & G. Galati)
- **VII SUPERIOR UPDATE COURSE ON CARDIOLOGY** (28-30 March 2019, Milan). He was **Moderator** during the session **Heart Failure** and was **presenter** during the session **“Pro & Contra: PCSK9 Inhibitors”**.
- **ANMCO REGIONAL CONGRESS (Lombardy)** (30 March 2019, Como). He was **expert discussant** during the session: “The difficult implementation of pharmacological therapy in Cardiology: innovations, complexity, follow-up management and poor compliance”.
- **HF ECO-ACADEMY 2.0. Presenter and Tutor**. During this training course he gave three presentation dedicated to Heart Failure: from epidemiology, to diagnosis and new therapies. (10<sup>th</sup> May 2019, Milan).
- **50<sup>th</sup> NATIONAL CONGRESS OF THE ITALIAN ASSOCIATION OF HOSPITAL CARDIOLOGISTS (ANMCO 2019)**. During this congress he presented an **E-poster** (18/May/2019): “The Difficult Antithrombotic Treatment Balance in a patient with Advanced Heart Failure and Atrial Fibrillation: Wisely sailing between Scylla and Charybdis”. session: “Stroke e Cardioembolismo,4”.
- **HEART FAILURE 2019 - 6TH WORLD CONGRESS ON ACUTE HEART FAILURE (25-28 May 2018, Vienna)**. During this congress he gave **a poster presentation** (25<sup>th</sup> of May) in the session: “Myocardial Disease”: “Clinical spectrum and outcome of advanced heart failure in hypertrophic cardiomyopathy: from pathophysiology to contemporary unmet needs”. Furthermore, he was named from the ESC: **“ESC Twitter Ambassador for Heart Failure 2019”**.
- **EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2019** (31 August-4 September 2019, Paris). During this congress he gave a presentation (01/09/2019) at the ESC Professional Member Lounge with this title: “Be a Twitter Pro” dedicated to how to share scientific papers in Cardiology on the Social Media and on Twitter. Furthermore, he was named by the ESC: **“ESC twitter Heart Failure Ambassador for ESC Congress 2019”**
- **HEART FAILURE: NOT END-STAGE BUT NEW STAGE – TELLING A NEW STORY** (20-21 September 2019, Rome). He participated as **moderator** during the session: **“Heart Failure and Diabetes: The Cardiologist Interviews the Diabetologist”**
- **SICOA REGIONAL CONGRESS (Lombardy): Updating in Cardiology** (30 November 2019, Milan). He gave a **presentation** during the II session, with the following title: “Heart Failure: what novelties in pharmacological therapy”
- **HEART FAILURE EXCELLENCE EXCHANGE** (three parts: June 2020) organized by **the University of Glasgow** and by **Astrazeneca**. He attended as discussant.
- **51<sup>th</sup> NATIONAL CONGRESS OF THE ITALIAN ASSOCIATION OF HOSPITAL CARDIOLOGISTS (ANMCO 2020). Presenter** in the **III session YOUNG ESC CONVENTION : DIABETES**: “How to reduce Cardiovascular Risk in a patient with Diabetes and Heart Failure”.
- **VIII SUPERIOR UPDATE COURSE ON CARDIOLOGY** (29-31 October 2020, Milan). **Speaker** in the **session Heart Failure**: **“Let’s predict the New Guidelines: How you will change the Diagnosis”** and in the **session Clinical Cardiology**: **“Sacubitril/Valsartan: To whom? When?”**. As **Moderator** in the **session Clinical Cardiology**: **“Therapy of Amyloidosis”**.
- **VIII NATIONAL CONGRESS OF ITALIAN SOCIETY OF CARDIOLOGY PRIVATE HOSPITALS (SICOA)** (9-11 November 2020, Online). **Speaker** in the session **Acute, Chronic, and Advanced Heart Failure**: **“Clinical profiles of Acute Heart Failure: can be useful a new classification?”**
- **MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES: formazione integrata** (26 November, Online). **Speaker** with the following presentation **“Heart Failure & Comorbidities”**.
- **V SICOA REGIONAL CONGRESS (Lombardy)**: (2 December 2020, Online). He gave a presentation during the **III Session**, with the following title: **“Heart Failure: the new oral antidiabetics are more useful for the cardiologist than to diabetologist?”**
- **Heart Failure 2020 Convention HF Centers: - Rewrite The Stars Streaming Session**. He gave a presentation in the **Young Investigator Session**, entitled: **“The Young Cardiologists of the European Society of Cardiology”** (5 December 2020, Online).
- **AHA Scientific Sessions 2020**. (13-17, November, 2020). He gave **a poster presentation**: “Classification of the different types of Hypertrophic Cardiomyopathy responsible for Advanced Heart Failure: from clinical, morpho-functional characteristics to prognosis and potential new therapies” n° #12790.
- **Heart Failure Forum: What changes in HF treatment after the recent trials** (19-20, March 2021, Online). He gave a presentation in the **Session Clinical Experience in HF management**, entitled: **“SGLT2i”**.
- **ANMCO REGIONAL CONGRESS (Lombardy)** (16-17<sup>th</sup> April 2021, Online). He gave a presentation in the session: **Meanwhile in Chronic Heart Failure: “SGLT2i: the fourth Ace?”**.
- **XIX NATIONAL CONGRESS OF ITALIAN SOCIETY OF CARDIOLOGY PRIVATE HOSPITALS (SICOA)** (24-26 June 2021, Online). **Moderator & Discussant** in the session **SYMPOSIUM ON HEART FAILURE**.
- **IX SUPERIOR UPDATE COURSE ON CARDIOLOGY** (1-3 July 2021, Milan & online). **Speaker** in the **IV Symposium Clinical Cardiology – Heart Failure 1** with the following presentation **“La terapia inotropica nell’insufficienza cardiaca: una opzione praticabile?”** & in the **PRO & CONTRA session: ARNI Subito?** with the following presentation **“ARNI subito: Pro”**.
- **MODERN MANAGEMENT OF HEART FAILURE: Italian Heart Failure Association** (2-3 July 2021, Naples & online). He gave a presentation in the **VIII Session SGLT2i in Heart Failure: Beyond Diabetes** with this title **“SGLT2i Mechanisms of action: beyond the renal system”**.

- **Multidisciplinary Approach to DOACs therapy: Last Evidences** (29 September 2021, Milan). He gave the following presentation “La complessità del paziente con scompenso in terapia Anticoagulante: districarsi tra i diversi profili di rischio emorragico ed ischemico”.
- **NATIONAL SICOA SEMINAR ON HEART FAILURE** (12-13 November 2021, Naples). He gave a presentation in the IV Session **Cardiologist and Diabetes** with this title “**Clinical use of SGLT2i**”.
- **HEART FAILURE TALK** (25<sup>th</sup> November 2021, Milan), He gave the following presentations: “**Gestione dello Scompenso Cardiaco nella pratica clinica reale**” and “**Il paziente ospedalizzato in terapia subottimale, con comorbidità e/ portatore di device**”.
- **MEDSCAPE Teaching Video: Atrial Fibrillation and Peripheral Artery Disease** (30 November 2021).
- **Heart Failure: The Golden Touch** (16-17 December 2021, Rome & Online). Presenter at the session **Women and Young community in Heart Failure** with this presentation: “**Progetto ESC Heart Failure of Tomorrow**”.
- **X SUPERIOR UPDATE COURSE ON CARDIOLOGY** (24-26 March 2022, Milan). **Speaker in the IV Symposium on Clinical Cardiology- Heart Failure 1**. He gave the following presentation: “**HFPEF: Finally an effective therapy?**”.
- **ESC Acute CardioVascular Care 2022** (24-26 Marzo 2022, Marseille, & Online). He presented 2 posters: “**Atrial fibrillation: the difference in thromboembolic events prognosis**” and “**Regular heart rhythm restoration after a period of asystole: modeling in experimental cardiology**”.
- **SCIENTIFIC RESPONSIBLE AND ORGANIZATOR of “FIRST NATIONAL MEETING OF ITALIAN HEART FAILURE OF TOMORROW”** (6 & 7 May 2022, MILAN) under the umbrella of the HFA & of ITAHFA. During this congress he **MODERATED** and **CHAIR**ED MANY SESSIONS and he gave 2 **LECTURES** with this title: “**SGLT2i: THE STATINS OF THE 21ST CENTURY? INDICATIONS & MULTIPLE MECHANISMS OF BENEFIT**” & “**THE GMPC PATHWAY & THE ROLE OF VERICIGUAT IN WORSENING HEART FAILURE**”. Moreover he **COORDINATED 4 National Research Projects on Heart Failure**.
- **Heart Failure 2022** (21-24 May 2022, Madrid & Online). He presented a poster “**Hemodynamic arterial changes in heart failure. Shifting the paradigm from "heart" to "heart & vessels failure". The Copernican Revolution**”.
- **MODERN MANAGEMENT OF HEART FAILURE: Italian Heart Failure Association** (3-4 June 2022, Florence & online). **Speaker** in the X Session: **THE PROFILE OF HEART FAILURE PATIENT** with this title: “**TREATMENT OF HF PATIENTS WITH DIFFERENT LEVEL OF HEART RATE AND BLOOD PRESSURE**”.
- **GREY ZONES 2022** (9-11 June, Bergamo). **Discussant and Expert Opinion** in the Session “**UNCERTAINTIES IN THE HEART FAILURE TREATMENT**”.
- **XX NATIONAL CONGRESS OF ITALIAN SOCIETY OF CARDIOLOGY PRIVATE HOSPITALS (SICOA)** (23-25 June 2022, Naples & Online). **Speaker** in the VI session: **Heart Failure Guidelines 2021** with this title: “**HEART FAILURE PHENOTYPING: OLD & NEW CLASSIFICATIONS**”.
- **e-SPACE HEART FAILURE 2022 VIRTUAL CONFERENCE** (14-15 October 2022, Online). **Chair of the IV Session: MANAGING YOUR HF PATIENTS WITH COMORBIDITIES (part 2)**.
- **WEBINAR ANMCO** (26 October 2022, Online). **HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (LVEF>40 & <50%): HOW WE SHOULD TREAT AS HFREF OR AS HFPEF? Speaker** with this title: “**HFREF SHOULD BE TREATED AS HFPEF**”.
- **HEART FAILURE: NEW THERAPEUTIC STRATEGIES IN THE COMPLEX PATIENT** (4-5 November 2022, Coccaglio BS). **Speaker** with this title: “**HEART FAILURE PATIENT AND RENAL COMORBIDITY**”.
- **VII SICOA REGIONAL CONGRESS**: (26 November 2022, Milan). **Speaker** in the **Session I** with the following title: “**SGLT2i ROLE IN HEART FAILURE ACROSS THE FULL SPECTRUM OF EJECTION FRACTION**”.
- **NATIONAL SICOA SEMINAR ON HEART FAILURE MANAGEMENT** (2 December 2022, Rome). **Speaker** in Part II with this title: “**HFpEF: CAN SCORES HELP IN DIAGNOSIS?**”.
- **CARDIOVISION: Nutraceutical approach to cardiovascular health** (April 1, 2023, Milan). **Speaker** in Session 1 with the following lecture: “**Cardiovascular risk stratification: from risk algorithms to new cardiovascular risk factors**”.
- **1 st Permanent Academy on Cardiometabolic Prevention in Clinical Practice** (14 Aprile 2023, Bologna). **Speaker** in Session 1 - Cardiovascular with this title: “**New approach to heart failure: SGLT2 inhibitors and beyond**”.

## ➤ **HONORS, AWARDS, LEADERSHIP**

- **FELLOW OF THE HEART FAILURE ASSOCIATION OF THE ESC** : MARCH 2021- PRESENT
- **HFA TRAVEL GRANT HEART FAILURE ASSOCIATION (HFA) OF THE ESC** : MAY 2019
- **HEART FAILURE SPECIALISTS OF TOMORROW (HOT) REPRESENTATIVE AND COORDINATOR FOR ITALY**: OCTOBER 2021 -PRESENT
- **ITALIAN FEDERATION OF CARDIOLOGY (IFC) YOUNG AMBASSADOR FOR HEART FAILURE ASSOCIATION (HFA) OF THE ESC**: 2019-PRESENT
- **INTERNATIONAL HEART FAILURE CLINICIAN AWARD 2021**. FROM THE **PUMPING MARVELLOUS FOUNDATION, PRESTON, UK**

## ➤ **ADVISORY BOARDS**

- **Local Advisory Board**: “Local Panels 2021 Lombardia - Approccio multidisciplinare nel paziente cardio-metabolico: identificare e comprendere i possibili percorsi di gestione e cura” (18th June 2021, Online). **Boehringer Ingelheim and Lilly**

- **International Advisory Board: CVRM Digital Expert Think Tank Advisory Board** (5<sup>th</sup> July, 2021, Online). **Astrazeneca**
- **International Advisory Board: Medical Education in Social Media Consultancy** (17<sup>th</sup> Nov 2021, Online). **Boehringer Ingelheim**
- **International Advisory Board: CVRM Digital Expert Think Tank Advisory Board** (14<sup>th</sup> & 28<sup>th</sup> July, 2022, Online). **Astrazeneca**
- **National Advisory Board: Expert Input Forum: Digital Opinion Leaders** (5<sup>th</sup> December 2022, Milan). **Amarin Corporation**

## ➤ KNOWLEDGE OF FOREIGN LANGUAGES

### English

Self-assessment	Understanding		Speaking		Writing
	Listening	Reading	Spoken interaction	Spoken production	
<b>European level</b>	<b>C2: Proficiency</b>	<b>C2: Proficiency</b>	<b>C2: Proficiency</b>	<b>C2: Proficiency</b>	<b>C2: Proficiency</b>

- **First Certificate in English – FCE. Passed at Grade B, on 01/06/2016.**
- **Certificate of the British School Group, which attests the 8th level of English (C2, Proficiency) released on 01/07/2020**
- **Certificate of the British School Group, which attests the seventh level of English (C1, Advanced) released on 10/06/2019.** On achieving the following grades: Reading&Writing: Good, Speaking&Listening: Merit, after he attend a one-year course of English.
- **Certificate of the British School Group, which attests the sixth level of English (C1, Business Advanced) released on 18/07/2017.** On achieving the following grades: Reading&Writing: Good, Speaking&Listening: Good, after he attended a one-year course of English.
- **Certificate of the British School Group, which attests the fifth level of English (B2, Upper-Intermediate) - released on 8/06/2016.** On achieving the following grades: Reading&Writing: Distinction, Speaking&Listening: Merit, after he attended a course of English.
- **Statement/certificate - released on 30/06/2015 from British School Group – which attests the B1+ level of English, after he attended an individual course of English with contents of Medical English.**

## ➤ COMPUTER SKILLS

Hardware: Capability to use Graphic Workstations.

Operating Systems: Starting from Windows 95 to Windows 10.0, Mac and IOS

Software: Excellent knowledge of the major softwares, in particular: Microsoft Office (Word, Excel, Power Point); Database management; excellent knowledge of the major graphic softwares.

Advanced Software: TOMTEC Imaging System (cardiovascular ultrasound imaging post-processing), Image Pro-Plus 7.0, histometric analysis program.

Ability to use the major echocardiographic softwares: Philips, GE, Esaote.

## LIST OF PUBLICATIONS

1. **Galati Giuseppe**, Leone O, Rapezzi C. The difficult diagnosis of isolated cardiac sarcoidosis: usefulness of an integrated MRI and PET approach. **Heart** 2014; 100:89–90.
2. **Galati Giuseppe**, Rapezzi C. Myocardial amyloid infiltration: a less than expected homogeneous process. **Heart** 2014; 100:1659– 1660.
3. **Galati Giuseppe**, Leone O, Pasquale F, Olivetto I, Biagini E, Grigioni F, Pilato E, Lorenzini M, Corti B, Foà A, Agostini V, Cecchi F, Rapezzi C. Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts. **Circulation Heart Failure** 2016; 9:e003090.
4. Sabouret P and **Galati Giuseppe** (First Co-Author), Angoulvant D, Germanova O, Castelletti S, Pathak A, Metra M, Margonato A. The Interplay Between Cardiology And Diabetology: A Renewed Collaboration To Optimize Cardiovascular Prevention And Heart Failure Management. **European Heart Journal Cardiovascular Pharmacotherapy** 2020; 6:394-404.
5. Di Fusco SA, Rossini R, Flori M, Pollaro L, Ingiani N, Malvezzi Caracciolo D'Aquino M, **Galati Giuseppe**, Zilio F, Iorio A, Scotto di Uccio F, Lucà F, Gulizia MM, Ciccirillo F, Gabrielli D, Colivicchi F. Pathophysiology and management of recreational drug-related acute coronary syndrome: ANMCO position statement. **Journal of Cardiovascular Medicine** 2021; 22:79-89.
6. Margonato D, **Galati Giuseppe**, Mazzetti S, Cannistraci R, Perseghin G, Margonato A, Mortara A. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. **Heart Failure Reviews** 2020; 26:337-345.
7. Germanova O, Shchukin Y, Germanov V, **Galati Giuseppe**, Germanov A. Extrasystolic arrhythmia: is it an additional risk factor of atherosclerosis? **Minerva Cardiology and Angiology.** 2022; 70:32-39. DOI: 10.23736/s2724-5683.20.05490-0
8. Germanova OA, Germanov VA, Shchukin YV, Germanov AV, Piskunov MV, Burmistrov AE, Yusupov RY, **Galati Giuseppe**. Modeling of restenosis of main arteries after the intravascular stenting interventions. **Science and Innovations in Medicine** 2021; 6:45-49.
9. Germanova O, **Galati Giuseppe**, Germanov V, Prokhorenko I, Germanov A. Atrial Fibrillation: is it an additional risk factor of atherosclerosis? **J Angiol Vasc Surg** 2021; 6:065



10. Galati Giuseppe, Germanova O, Iozzo RV, Buraschi S, Shchukin YV, Germanov A, Germanov V, Tereshina O, Senni M, Margonato A. Hemodynamic Arterial Changes in Heart Failure: A Proposed new Paradigm of "Heart and Vessels Failure (HVF)". **Minerva Cardiology and Angiology** 2022; 70:310-20. doi: 10.23736/S2724-5683.21.05786-0.
11. Germanova OA, Galati Giuseppe, Germanov VA, Shchukin YV, Germanov AV. Extrasystolic arrhythmia – an unaccounted risk factor of atherosclerosis development in main arteries? **Science and Innovations in Medicine** 2021; 6:48-53.
12. Galati Giuseppe, Sabouret P, Germanova O, Bhatt DL. Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. **European Cardiology Review** 2021;16:e40; <https://doi.org/10.15420/ecr.2021.22>
13. Sabouret P, Bocchino PP, Angelini F, D'Ascenzo F, Giuseppe Galati, Fysekidis M, De Ferrari GM, Fischman DL, Bhatt DL, Biondi-Zoccai G. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. **Minerva Cardiology and Angiology** 2022; Feb 23. doi: 10.23736/S2724-5683.22.05900-2
14. Germanova O, Galati Giuseppe, Germanov A, Stefanidis A. Atrial fibrillation: a new independent risk factor for thromboembolic events - hemodynamics and vascular consequence of long ventricular pauses. **Minerva Cardiology and Angiology** 2022; Mar 25. doi: 10.23736/S2724-5683.22.06000-8
15. Vukolova Y, Gubareva I, Galati Giuseppe, Germanova O. Proprotein convertase subtilisin kexin type 9 and main arteries atherosclerosis in patients with arterial hypertension. **Minerva Cardiology and Angiology** 2022, Apr. DOI: 10.23736/s2724-5683.22.06008-2. PMID: 35420281.
16. Germanova O.A., Germanov A.V., Shchukin Y.V., Galati Giuseppe. Extrasystolic arrhythmia: is it an additional risk factor of cryptogenic stroke? **Science and Innovations in Medicine** 2022; 7:89-94. doi: 10.35693/2500-1388-2022-7-2-89-94
17. Germanova OA, Germanov AV, Galati Giuseppe, Prokhorenko IO, Germanov VA. Cryptogenic stroke in atrial fibrillation without intra-heart thrombi: possible mechanisms. **Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)** 2022; 2 doi: 10.20340/vmi-rvz.2022.2.clin.7
18. Gulizia MM, Orso F, Mortara A, Lucci D, Aspromonte N, De Luca L, Di Tano G, Leonardi G, Navazio A, Pulignano G, Colivicchi F, Di Lenarda A, Oliva F et al; BLITZ-HF Investigators\* (Galati Giuseppe). BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines. **Eur J Heart Fail.** 2022 Jul 3. doi: 10.1002/ehjhf.2605
19. Germanova O, Galati Giuseppe, Vachev A, Germanov A, Biondi-Zoccai G. The operation of carotid endarterectomy: is it an effective method of treatment of arterial hypertension? **Panminerva Medica** 2022; June. <https://doi.org/10.23736/s0031-0808.21.04608-5>
20. Germanova O, Galati Giuseppe, Usenova A, Germanov A. Modeling of intra-arterial circulation: Application in experimental cardiology. **Archiv EuroMedica** 2022. 12; 4: e1. doi 10.35630/2199-885X/2022/12/4.8
21. Germanova O, Galati Giuseppe, Usenova A, Germanov A. Premature ventricular contractions: the novel independent risk factor of cryptogenic stroke. **Archiv EuroMedica.** 2022. 12; 5: e1. doi 10.35630/2199-885X/2022/12/5.15
22. Germanova O, Smirnova D, Usenova A, Tavormina G, Cumming P, Galati Giuseppe. Cryptogenic stroke in the context of pandemic- related stress: the role of arterial hemodynamics. **Psychiatr Danub.** 2022 Sep;34 (Suppl 8):256-261. PMID: 36170739.
23. Germanova O, Galati Giuseppe, Vachev A, Germanov A, Biondi-Zoccai G. Carotid endarterectomy: the optimal surgical technique from the point of view of cardiologist. **Chirurgia** 2022; 35:355-62.
24. Fedorina M, Davydkin I, Galati Giuseppe, Biondi-Zoccai G, Germanova O. Carotid Bifurcation Stenosis: Functional Importance In Physical Exercises. **Italian Journal of Vascular and Endovascular Surgery** 2023; 30:11-4. doi: 10.23736/s1824-4777.22.01572-8
25. Sabouret P, Manzo-Silberman S, Alasnag M, Fysekidis M, Gulati M, Galati Giuseppe, Spadafora L, Banach M, Biondi-Zoccai G, Bhatt DL. New approaches to reduce recurrent PCI: to angioplasty and beyond! **Eur Heart J Open.** 2023; 3 (3):oead049. doi: 10.1093/ehjopen/oead049.

## BOOK CHAPTERS

1. Galati Giuseppe. New advances in Sudden Cardiac Death (SCD) Risk Stratification in Hypertrophic Cardiomyopathy (Chapter 7) in "Sudden Cardiac Death (SCD): Prevalence, Predictors and Clinical Perspectives". Nova Science Publishers 2017 - ISBN: 978-1-53611-983-1. June 2017.

## ABSTRACTS

1. Ciliberti P, Quarta CC, Riva L, Longhi S, Biagini E, Graziosi M, Terzi F, Galati Giuseppe, Branzi A, Rapezzi C. Amiloidosi ereditaria da mutazione della transtiretina: caratterizzazione dei casi con interessamento cardiaco esclusivo o prevalente. **Giornale italiano di cardiologia** 2008, Volume 9 Suppl. 1 al n. 12, S70 (C233).
2. Quarta CC, Riva L, Ciliberti P, Longhi S, Salvi F, Pastorelli F, Galati Giuseppe, Biagini E, Cavo M, Branzi A, Rapezzi C. Analogies and differences between the three main types of systemic cardiac amyloidosis. **Journal of the American college of cardiology** 2009 Vol. 53, Number 10 Supplement A; 1033-175.

3. Ciliberti P, Quarta CC, Riva L, Longhi S, Salvi F, Biagini E, **Galati Giuseppe**, Branzi A, Rapezzi C. Hereditary transthyretin-related amyloidosis with predominant or exclusive cardiac phenotype in a white Caucasian population. **Journal of the American college of cardiology** 2009 Vol. 53, Number 10 Supplement A; 1033-180.
4. Quarta CC, Ciliberti P, Longhi S, Riva L, Biagini E, Guidalotti PL, Pettinato C, **Galati Giuseppe**, Branzi A, Rapezzi C. Diagnostic accuracy of differential <sup>99</sup>Tc-DPD myocardial uptake in transthyretin-related and primary systemic cardiac amyloidosis. **Journal of the American college of cardiology** 2009 Vol. 53, Number 10 Supplement A; 1033-206.
5. Quarta CC, Riva L, Perlini S, Longhi S, Ciliberti P, Fonte ML, **Galati Giuseppe**, Biagini E, Merlini GP, Rapezzi C. The systemic cardiac amyloidoses: disease profiles and clinical course of the three main etiologic forms. **European Heart Journal** 2009, 30 (Abstract Supplement), 24 (P344).
6. Ciliberti P, Quarta CC, Riva L, Longhi S, **Galati Giuseppe**, Villani C, Salvi F, Lorenzini M, Branzi A, Rapezzi C. Hereditary transthyretin-related amyloidosis with exclusive cardiac phenotype. **European Heart Journal** 2009, 30 (Abstract Supplement), 539 (P3236).
7. Riva L, Quarta CC, Longhi S, Guidalotti PL, Ciliberti P, **Galati Giuseppe**, Biagini E, Pettinato C, Branzi A, Rapezzi C. Tc99-DPD scintigraphy can detect early myocardial amyloid deposition in transthyretin-related familial amyloid polyneuropathy. **European Heart Journal** 2009, 30 (Abstract Supplement), 540 (P3239).
8. Ciliberti P, Quarta CC, Perlini S, Riva L, Salvi F, **Galati Giuseppe**, Ferlini A, Obici L, Ferri A, Villani C, Branzi A, Merlini G, Rapezzi C. Hereditary transthyretin-related amyloidosis with exclusive cardiac phenotype: a multicenter italian study on 154 patients. **Giornale italiano di cardiologia** 2009, Volume 10 Suppl. 1 al n. 11-12; S198 (P155).
9. Quarta CC, Perlini S, Riva L, Ciliberti P, Longhi S, Leone O, Cavo M, **Galati Giuseppe**, Ferri A, Salvi F, Ferlini A, Villani C, Branzi A, Merlini G, Rapezzi C. The systemic cardiac amyloidoses: disease profiles and clinical courses of the three main etiologic forms. **Giornale italiano di cardiologia** 2009, Volume 10 Suppl. 1 al n. 11-12; S226 (P252).
10. Longhi S, Leone O, Quarta CC, Villani C, Gagliardi C, **Galati Giuseppe**, Rapezzi C. Patterns of myocardial infiltration in cardiac amyloidosis: a morphometric histologic study. **Amyloid** 2010, 17 (Supplement 1), 147-148 (P-116).
11. Quarta CC, Guidalotti PL, Longhi S, Ciliberti P, Leone O, **Galati Giuseppe**, Ferlini A, Biagini E, Villani C, Gagliardi C, Pettinato C, Rapezzi C. <sup>99m</sup>TcDPD scintigraphy detects transthyretin cardiac amyloidosis across a wide spectrum of involvement. **Amyloid** 2010, 17 (Supplement 1), 161 (P-138).
12. Longhi S., Leone O., Quarta C., **Galati Giuseppe**, Gagliardi C., Villani C., Lorenzini M., Lai F., Rapezzi C. Patterns of myocardial infiltration in cardiac amyloidosis: a morphometric histologic study. **European Heart Journal** 2010, 31 (Abstract Supplement), 39 (P448).
13. Fantini L, Quarta LC, Guidalotti P, Longhi S, Ciliberti P, Leone O, **Galati Giuseppe**, Ferlini A, Biagini E, Villani C, Gagliardi C, Pettinato C, Fanti S, Rapezzi C. <sup>99m</sup>TcDPD scintigraphy detects transthyretin cardiac amyloidosis across a wide spectrum of involvement. **European Journal of Nuclear Medicine and Molecular Imaging** 2011, 38 (Supplement 2), S421 (P685).
14. **Galati Giuseppe**, Leone O., Biagini E., Pasquale F., Mingardi F., Grigioni F., Rapezzi C. Heterogeneity of patterns and distribution of myocardial fibrosis in end-stage Hypertrophic Cardiomyopathy (ES-HCM) undergoing heart transplant: a morphometric analysis of 24 explanted hearts. **European Heart Journal** 2015, 36 (Abstract Supplement), 952 (P5468)
15. **Galati Giuseppe**, Leone O., Pasquale F., Biagini E., Grigioni F, Pilato E, Rapezzi C. Histologic and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: clinical and pathological comparison in 31 explanted hearts. **Accepted and Presented Abstract al 76° Congresso della Società Italiana di Cardiologia- SIC - Roma, 11-14 Dicembre 2015 (N° 226)**.
16. **Galati Giuseppe**, Leone O., Pasquale F., Biagini E., Grigioni F., Pilato E., Rapezzi C. Histologic and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts. **European Journal of Heart Failure** 2016, 18 (Supplement 1), 132-133 (P522).
17. **Galati Giuseppe**, Leone O., Pasquale F., Olivotto I., Biagini E., Grigioni F, Pilato E, Cecchi F, Rapezzi C. Histologic and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study in 31 explanted hearts. **Minerva Cardioangiologica** 2016, 64 (Supplemento 1 al n° 3), 216-17 (C431).
18. **Galati Giuseppe**, Leone O., Pasquale F., Biagini E., Olivotto I., Grigioni F., Pilato E., Cecchi F., Rapezzi C. Extent, type, patterns and distribution of myocardial fibrosis in end-stage HCM: an histologic-histometric analysis of 30 explanted hearts and comparison of LGE-CMR with histological fibrosis. **European Heart Journal** 2016, 37 (Abstract Supplement), 224 (P1186).
19. **Galati Giuseppe**, Pasquale F., Leone O., Olivotto I., Grigioni F., Pilato E., Biagini E., Cecchi F., Rapezzi C. Comparison between LGE-CMR and histomorphometric quantification of myocardial fibrosis in transplanted hearts for end-stage HCM. **European Journal of Heart Failure** 2017, 19 (Supplement 1), 432-433 (P1761).
20. **Galati Giuseppe**, Pasquale F., Leone O., Olivotto I., Grigioni F., Pilato E., Biagini E., Cecchi F., Rapezzi C. Comparison between LGE-CMR and histomorphometric quantification of myocardial fibrosis in transplanted hearts for end-stage hypertrophic cardiomyopathy (HCM). **Eur Heart J Cardiovasc Imaging** 2017, (Abstracts Supplement), O24.

21. **Galati Giuseppe**, Pasquale F., Leone O., Olivetto I., Grigioni F., Pilato E., Biagini E., Cecchi F., Rapezzi C. Accuracy of LGE-CMR compared with histometric quantification of myocardial fibrosis in transplanted hearts of end-stage HCM. **European Heart Journal** 2017, 38 (Supplement 1), 942 (P4497).
22. **Galati Giuseppe**, Di Lenarda A., Margonato A. Clinical-pathological profiles responsible for advanced heart failure, heart transplantation, left ventricular assist device implantation and death for heart failure in Hypertrophic cardiomyopathy. **European Journal of Heart Failure** 2018, 20 (Supplement S1), 493 (P1906).
23. **Galati Giuseppe**, Di Lenarda A., Margonato A. Clinical-pathological profiles responsible for advanced heart failure, heart transplantation, left ventricular assist device implantation and death for heart failure in Hypertrophic cardiomyopathy. **Minerva Cardioangiologica** 2018, 66 (Supplemento 1 al n° 3), 185-86 (C111).
24. **Galati Giuseppe**, Di Lenarda A., Cappelletti A., Volpe M., Ancona F., Mazzavillani M., Magni V., Capogrosso C., Stella S., Castelvechio S., Margonato A. Clinicopathological profiles responsible for advanced heart failure, heart transplantation, left ventricular assist device implantation and death for heart failure in Hypertrophic cardiomyopathy. **European Heart Journal** 2018, 39 (Abstract Supplement), 516 (P2597).
25. **Galati Giuseppe**, Leone O., Cappelletti A., Molfetta R., Volpe M., Ancona F., Magni V., Capogrosso C., Stella S., Castelvechio S., Rapezzi C., Margonato A. Coronary microvascular pathology as the major determinant of severe fibrosis in end-stage hypertrophic cardiomyopathy (HCM). **European Heart Journal** 2018, 39 (Abstract Supplement), 512 (P2585).
26. **Galati Giuseppe**, Pozniak KN, Margonato A. "The Difficult Antithrombotic Treatment Balance in a patient with Advanced Heart Failure and Atrial Fibrillation: Wisely sailing between Scylla and Charybdis". **European Heart Journal Supplements** 2019, 21 (Supplement E), E139 (P116).
27. **Galati Giuseppe**, Pozniak KN, Margonato A. "Il difficile equilibrio del trattamento antitrombotico in un paziente con scompenso cardiaco avanzato e fibrillazione atriale: navigare saggiamente tra Scilla e Cariddi". **Giornale Italiano di Cardiologia** 2019 **Supplemento 1 al N° 5**, 20, 85S (P120).
28. **Galati Giuseppe**, Zieroth S, Di Lenarda A, Aspromonte N, Vranic I, Gulizia M, Margonato A. Clinical spectrum and outcome of advanced heart failure in hypertrophic cardiomyopathy: from pathophysiology to contemporary unmet needs. **European Journal of Heart Failure** 2019, 21 (Suppl. S1), 127-128 (P520)
29. **Galati Giuseppe**, Germanova O, Aspromonte N, Sabouret P, Zieroth S, Cappelletti A, Vranic I, Metra M, Margonato A. Classification of different types of hypertrophic cardiomyopathy responsible for advanced heart failure: from the clinical, morpho-functional characteristics to prognosis and potential new therapies. **European Journal of Heart Failure** 2020, 22 (Suppl. S1), 122-123 (P634).
30. **Galati Giuseppe**, Germanova O, Aspromonte N, Sabouret P, Zieroth S, Cappelletti A, Vranic I, Metra M, Margonato A. Classification of different types of hypertrophic cardiomyopathy (HCM) responsible for advanced heart failure (AdvHF): from the clinical, morpho-functional and histopathological characteristics to prognosis and potential new therapies. **European Heart Journal Supplements** 2020, 22 (Supplement G), C46 (Pg20).
31. **Galati Giuseppe**, Germanova O, Aspromonte N, Sabouret P, Zieroth S, Cappelletti A, Vranic I, Metra M, Margonato A. Classificazione dei diversi tipo di Cardiomiopatia Ipertrofica responsabili di scompenso cardiaco avanzato: dalle caratteristiche cliniche e morfofunzionali alla prognosi ed alle nuove terapie potenziali. **Giornale Italiano di Cardiologia** 2020, **Supplemento 1 al N° 8**, 2, C46 (Pe18).
32. **Galati Giuseppe**, Germanova O, Sabouret P, Aspromonte N, Dalla Vecchia LA, Vranic I, Senni M, Metra M, Margonato A. Classification Of The Different Types Of Hypertrophic Cardiomyopathy Responsible For Advanced Heart Failure: From Clinical, Morphofunctional Characteristics To Prognosis And Potential New Therapies. **Circulation**. 2020; 142:A12790. [https://doi.org/10.1161/circ.142.suppl\\_3.12790](https://doi.org/10.1161/circ.142.suppl_3.12790).
33. Germanova O, **Galati Giuseppe**, Shchukin YV, Germanov AV, Germanov VA, Ryabov AE. Heart failure: the influence of different types on the main arteries kinetics. **Eur Heart J Acute Cardiovasc Care** 2021, 10, Supplement 1, zuab020. 040.
34. **Galati Giuseppe**, Germanova O, Iozzo RV, Buraschi S, Shchukin YV, Germanov A, Germanov V, Tereshina O, Senni M, Margonato A. Hemodynamic Arterial Changes in Heart Failure. A Proposed new Paradigm of Heart and Vessels Failure. **European Journal of Heart Failure** 2021, 23 (Supplement S2), 34.
35. Germanova OA, Germanov AV, **Galati Giuseppe**, Shchukin YV. Symptomatic arterial hypertension in extrasystolic arrhythmia. **European Journal of Cardiovascular Nursing** 2021, 20, Supplement 1, zvab060. 147.
36. Germanova OA, Germanov VA, **Galati Giuseppe**, Germanov AV, Shchukin YV. Extrasystolic arrhythmia as a risk factor of atherosclerosis. **European Journal of Cardiovascular Nursing** 2021, 20, Supplement 1, zvab060. 148
37. **Galati Giuseppe**, Germanova O, Iozzo RV, Buraschi S, Shchukin YV, Germanov A, Germanov V, Tereshina O, Senni M, Margonato A. Hemodynamic arterial changes in heart failure. a proposed new paradigm of heart and vessels failure. The copernican revolution? **European Heart Journal** 2021; 42 (Supplement\_1), ehab724.0759
38. Germanova OA, Germanov VA, Shchukin YV, Germanov AV, **Galati Giuseppe**. Device for modeling of intra-arterial circulation: application in experimental cardiology. **European Heart Journal** 2021; 42 (Supplement\_1), ehab724.0299

39. Galati Giuseppe, Germanova OA, Iozzo RV, Buraschi S, Germanov A, Germanov V, Fedorina M, Senni M, Margonato A. Haemodynamic arterial changes in heart failure: a proposed new paradigm of heart and vessels failure. The Copernican revolution? **European Heart Journal Supplements** 2021, 23 (Supplement\_G), suab139. 016
40. Germanova O, Galati Giuseppe, Germanov AV, Shchukin YV, Fedorina MA. Modeling of intra-arterial hemodynamics in main arteries atherosclerosis. **European Heart Journal - Cardiovascular Imaging** 2022, 23, (Supplement\_1), jeab289.345.
41. Germanova O, Germanov AV, Fedorina MA, Galati Giuseppe, Germanov VA. Regular heart rhythm restoration after a period of asystole: modeling in experimental cardiology. **European Heart Journal. Acute Cardiovascular Care** 2022, 11, Supplement\_1, zuac041.023.
41. Germanova O, Galati Giuseppe, Germanov AV. Atrial fibrillation: the difference in thromboembolic events prognosis. **European Heart Journal. Acute Cardiovascular Care** 2022, 11, Supplement\_1, zuac041.011.
42. Galati Giuseppe, Germanova O, Iozzo RV, Buraschi S, Germanov A, Germanov V, Senni M, Margonato A. Hemodynamic arterial changes in heart failure. Shifting the paradigm from "heart" to "heart & vessels failure". The Copernican Revolution. **European Journal of Heart Failure** 2022; 24, Suppl. S2, 3–282
43. Germanova O, Galati Giuseppe, A. Germanov. Cryptogenic stroke: the riddle with possible solution. **Atherosclerosis** 2022; 355,100.
44. Germanova O, Galati Giuseppe, A. Germanov. Modeling of hemodynamically significant atherosclerotic stenosis of main arteries in experimental cardiology. **Atherosclerosis** 2022; 355, 44.
45. Germanova O, Germanov AV, Galati Giuseppe. Cryptogenic stroke and extrasystolic arrhythmia: is there any correlation? **European Heart Journal** 2022; 43 (Supplement\_2), ehac544. 369
46. Germanova, Usenova A, Galati Giuseppe. Premature ventricular contractions: the role in arterial atherosclerosis pathogenesis. **European Heart Journal. Acute Cardiovascular Care** 2023; 12 (Supplement\_1), zuad036.009.
47. Germanova, Usenova A, Galati Giuseppe. Stroke in permanent atrial fibrillation: non-cardiac sources mechanisms. **European Heart Journal. Acute Cardiovascular Care** 2023; 12 (Supplement\_1), zuad036.004,
47. Germanova, Germanov V, Galati Giuseppe Modeling of main arteries restenosis in experimental cardiology. **European Heart Journal. Acute Cardiovascular Care** 2023, 12, (Supplement\_1), zuad036.166

Milan, 11<sup>th</sup> June 2023

Doctor Giuseppe Galati

